These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31278808)

  • 21. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil.
    Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M
    Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
    Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
    Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost of Pediatric Visceral Leishmaniasis Care in Morocco.
    Tachfouti N; Najdi A; Alonso S; Sicuri E; Laamrani El Idrissi A; Nejjari C; Picado A
    PLoS One; 2016; 11(6):e0155482. PubMed ID: 27257808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil.
    Carvalho JP; Assis TM; Simões TC; Cota G
    Rev Soc Bras Med Trop; 2021; 54():e04542020. PubMed ID: 33533816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
    Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.
    Ramos JM; Clavijo A; Moral L; Gavilan C; Salvador T; González de Dios J
    Paediatr Int Child Health; 2018 Aug; 38(3):203-208. PubMed ID: 29790825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
    Sundar S; Goyal AK; More DK; Singh MK; Murray HW
    Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Visceral leishmaniasis: new drugs].
    Minodier P; Robert S; Retornaz K; Garnier JM
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating drug resistance in visceral leishmaniasis: the challenges.
    Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
    Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis.
    Kato KC; de Morais-Teixeira E; Islam A; Leite MF; Demicheli C; de Castro WV; Corrêa-Junior JD; Rabello A; Frézard F
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.
    Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M
    Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case.
    Gomes MAF; Medeiros LLC; Lobo FPD; Wanderley NRS; Matos APR; Jácome TDN; Monteiro MGL; Luz KG
    Rev Soc Bras Med Trop; 2018; 51(3):393-396. PubMed ID: 29972577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.